Experiences, challenges, and their mitigation during COVID convalescent plasma donation management: Data from a single center in India
Background and Objectives: ICMR conducted a multicentric trial “PLACID” that allowed COVID convalescent plasma (CCP) as an experimental drug for the management of moderate COVID-19 disease and the authors' institute was one of the participating centers. The efficacy of CCP in COVID-19 is still...
Main Authors: | Geet Aggarwal, Aseem Kumar Tiwari, Swati Pabbi, Arghyadeep Marik, Ganesh Rawat, Jyoti Sharma, Nixon P Joseph, Vikash Vashisth, Govind Sharma |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
Series: | Global Journal of Transfusion Medicine |
Subjects: | |
Online Access: | http://www.gjtmonline.com/article.asp?issn=2468-8398;year=2022;volume=7;issue=1;spage=65;epage=70;aulast=Aggarwal |
Similar Items
-
Development and implementation of a COVID-19 convalescent plasma program in a middle-income economy
by: Gustavo de Carvalho Duarte, et al.
Published: (2022-04-01) -
Single Donor Plasmapheresis for COVID-19: An Experience from a Tertiary Care Hospital Based Blood Centre
by: Archana L Khade, et al.
Published: (2022-10-01) -
The predictors of high titer of anti-SARS-CoV-2 antibody of convalescent plasma donors
by: Shinta Oktya Wardhani, et al.
Published: (2021-07-01) -
COVID-19 convalescent plasma product: Harvesting plasma from single unit whole blood, a cost effective alternative to plasmapheresis
by: Sanmukh R Joshi
Published: (2020-01-01) -
Reinforcement of the Standard Therapy with Two Infusions of Convalescent Plasma for Patients with COVID-19: A Randomized Clinical Trial
by: Joan Bargay-Lleonart, et al.
Published: (2022-05-01)